دورية أكاديمية
أعرض في EDS

Mental health related adverse events of cytisine and varenicline in smokers with and without mental health disorders: Secondary analysis of a randomized controlled trial.

التفاصيل البيبلوغرافية
العنوان: Mental health related adverse events of cytisine and varenicline in smokers with and without mental health disorders: Secondary analysis of a randomized controlled trial.
المؤلفون: Rubaiya Talukder S; National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, New South Wales 2031, Australia. Electronic address: s.talukder@unsw.edu.au., Lappin J; National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, New South Wales 2031, Australia; Discipline of Psychiatry and Mental Health, University of New South Wales, Sydney 2200, Australia., Clare Boland V; National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, New South Wales 2031, Australia., Weaver N; School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, 2308, Australia., McRobbie H; National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, New South Wales 2031, Australia., James Courtney R; National Drug and Alcohol Research Centre, University of New South Wales, 22-32 King St, Randwick, New South Wales 2031, Australia.
المصدر: Addictive behaviors [Addict Behav] 2024 Dec; Vol. 159, pp. 108148. Date of Electronic Publication: 2024 Aug 29.
نوع المنشور: Journal Article; Randomized Controlled Trial
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: England NLM ID: 7603486 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-6327 (Electronic) Linking ISSN: 03064603 NLM ISO Abbreviation: Addict Behav Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Elsevier Science
Original Publication: Oxford, Elmsford, N. Y., Pergamon Press.
مواضيع طبية MeSH: Varenicline*/therapeutic use , Varenicline*/adverse effects , Quinolizines*/therapeutic use , Quinolizines*/adverse effects , Azocines*/therapeutic use , Azocines*/adverse effects , Alkaloids*/adverse effects , Alkaloids*/therapeutic use , Smoking Cessation*/methods , Smoking Cessation Agents*/therapeutic use , Smoking Cessation Agents*/adverse effects , Mental Disorders*/drug therapy , Mental Disorders*/epidemiology, Humans ; Male ; Female ; Middle Aged ; Adult ; Australia/epidemiology ; Quinolizidine Alkaloids
مستخلص: Introduction: Little is known about the adverse events (AEs) of cytisine versus varenicline among individuals with mental health disorders (MHDs), highlighting the necessity for further exploration to inform clinical practice. This secondary analysis of clinical trial data aimed to investigate the effect of varenicline vs. cytisine regarding mental-health-related AEs (MH-related AEs) on smokers with and without MHDs.
Methods: Australian daily smokers interested in quitting were randomised to varenicline (84 days) or cytisine (25 days) and categorised by self-reported MHD diagnosis or treatment in the past year (MHD or non-MHD groups). Treatment adherence was assessed by self-reported number of doses taken during the active treatment phase via two check-in calls (at one month), while AEs were evaluated through four phone interviews: two check-in calls (one month) and follow-up calls at four and seven months. Logistic regression analysis compared MH-related AEs between groups, including only participants taking at least one dose.
Results: Of 1452 smokers 246 reported MHDs, 725 received cytisine and 727 received varenicline. Median number of doses taken was comparable between MHD (34 cytisine and 12 varenicline) and non-MHD (33 cytisine and 13 varenicline) groups. MH-related AEs were: 14.1 % (n = 30) in MHD (12.5 % in cytisine and 15.4 % in varenicline), and 11.8 % (n = 126) in non-MHD group (10.9 % in cytisine and 13.7 % in varenicline). No significant difference in MH-related AE occurrence was identified between medication groups (aOR=0.96, 95 % CI 0.4 to 2.2, p-value = 0.94).
Conclusion: Comparable MH-related AEs were observed between smokers with and without MHDs, suggesting that cytisine, like varenicline, may be well-tolerated by those with MHDs. However, larger clinical trials focused on MH-related AEs are needed for more conclusive evidence.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
المشرفين على المادة: W6HS99O8ZO (Varenicline)
53S5U404NU (cytisine)
0 (Quinolizines)
0 (Azocines)
0 (Alkaloids)
0 (Smoking Cessation Agents)
0 (Quinolizidine Alkaloids)
تواريخ الأحداث: Date Created: 20240830 Date Completed: 20240908 Latest Revision: 20240908
رمز التحديث: 20240909
DOI: 10.1016/j.addbeh.2024.108148
PMID: 39213816
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-6327
DOI:10.1016/j.addbeh.2024.108148